Form 4 Filing for Processa Pharmaceuticals, Inc.

This filing details transactions by Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, Inc. (PCSA). Skibsted acquired 11,883 Restricted Stock Units (RSUs) with a transaction value of $0 on July 26, 2026. These RSUs represent a contingent right to receive one share of common stock, vesting upon grant but distributed later. Additionally, Skibsted holds 16,689 shares of common stock. Following the RSU acquisition, his total holdings of RSUs amount to 17,323 shares. The filing also mentions stock options vesting over three years, with the exact number of shares not specified in this transaction summary. All share amounts reflect a 1-for-25 reverse stock split effective December 17, 2025.